Immune response of horses to inactivated African horse sickness vaccines.

Authors: Rodríguez Marina, Joseph Sunitha, Pfeffer Martin, Raghavan Rekha, Wernery Ulrich

Journal: BMC veterinary research

DOI: 10.1186/s12917-020-02540-y PubMed: 32873300Log in to save

Summary

# Editorial Summary: Immune Response to Inactivated African Horse Sickness Vaccines African horse sickness remains a devastating threat to equine populations across sub-Saharan Africa, with centuries of documented impact on both animal welfare and economic productivity. Rodríguez Marina and colleagues investigated how horses mounted immune responses to inactivated AHS vaccines, moving away from reliance on the live attenuated vaccines currently used for prevention and vector control strategies. Their work examined antibody production and cellular immune markers following vaccination with inactivated viral preparations, providing data on the quality and persistence of protection generated. The findings are particularly relevant for practitioners in endemic regions seeking safer vaccination alternatives that eliminate risks associated with live vaccine strains, whilst contributing to understanding of which immune pathways require stimulation for effective protection against this high-mortality disease. For farriers, veterinarians, and equine professionals working with horses in at-risk areas, this research informs discussions about vaccination strategy refinement and helps identify whether inactivated vaccine approaches might offer viable, safer options alongside existing vector control measures.

Read the full abstract on PubMed

Practical Takeaways

•Understanding immune responses to inactivated vaccines may offer safer alternatives to live attenuated vaccines in AHS-endemic regions
•Vector control remains a critical component of AHS management alongside vaccination strategies
•Inactivated vaccine development could reduce disease transmission risk compared to live vaccine approaches in high-risk areas

Key Findings

•African horse sickness is a serious viral disease causing significant mortality and economic losses in equids across sub-Saharan Africa
•Current prevention and control strategies rely on live attenuated vaccines combined with arthropod vector control measures
•The study examines immune response mechanisms to inactivated AHS vaccines as an alternative vaccination approach

Conditions Studied

african horse sickness (ahs)

Related References

Humoral antibody response of 10 horses after vaccination against African horse sickness with an inactivated vaccine containing all 9 serotypes in one injection.

Wernery Ulrich, Rodriguez Marina, Raghavan Rekha, Syriac Ginu, Miriam Thomas M Shruti, Elizabeth Shyna K, Federico Ronchi Gaetano, Muhammed Rubeena, Patteril Nissy A, Joseph Sunitha(2021)Equine veterinary journal

Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness.

Rutkowska Daria A, Mokoena Nobalanda B, Tsekoa Tsepo L, Dibakwane Vusi S, O'Kennedy Martha M(2019)BMC veterinary research

Economic assessment of African horse sickness vaccine impact.

Redmond Elizabeth F, Jones Derrick, Rushton Jonathan(2022)Equine veterinary journal

Experimental infection of horses with African horse sickness virus results in overt disseminated intravascular coagulation.

Schliewert Eva Christina, Hooijberg Emma H, Goddard Amelia(2026)Equine veterinary journal

African horse sickness: The potential for an outbreak in disease-free regions and current disease control and elimination techniques.

Robin M, Page P, Archer D, Baylis M(2016)Equine veterinary journal